Company Filing History:
Years Active: 2024-2025
Title: Hina Andleeb: Innovator in Nicotinic Acetylcholine Receptor Research
Introduction
Hina Andleeb is a prominent inventor based in Boston, MA (US). She has made significant contributions to the field of pharmacology, particularly in the development of compounds that modulate nicotinic acetylcholine receptors. With a total of 2 patents to her name, her work is paving the way for advancements in therapeutic applications.
Latest Patents
Hina Andleeb's latest patents include innovative compounds such as N,N diethyl-N'phenylpiperazine alpha 7 and alpha 9 nicotinic acetylcholine receptor agonists and antagonists. These patents provide embodiments of para-substituted 1,1-dialkyl-4-phenylpiperazin-1-ium iodides that are advantageous for modulating inflammation. The synthesized compounds have been characterized for their electrophysiological activities on α9, α9α10, and α7 nAChRs. The para position of these compounds contains alkyl or aryl amides, or heterocyclic isosteres for the amide. The alkyl groups were varied at the ammonium piperazine nitrogen to assess the impact of size changes on function. The compounds demonstrated greater potency for α9-containing receptors compared to α7, with most acting as full or strong partial agonists for α9-containing nAChRs.
Career Highlights
Hina Andleeb is affiliated with the University of Florida Research Foundation, Incorporated. Her research focuses on the synthesis and characterization of novel compounds that target nicotinic acetylcholine receptors, contributing to the understanding of their role in inflammation and other physiological processes.
Collaborations
Hina collaborates with notable colleagues such as Nicole Alana Horenstein and Roger Lee Papke. Their combined expertise enhances the research efforts in the field of pharmacology and receptor modulation.
Conclusion
Hina Andleeb's innovative work in the development of nicotinic acetylcholine receptor modulators is making a significant impact in pharmacological research. Her contributions are essential for advancing therapeutic strategies in treating various conditions related to inflammation and receptor activity.